Cancer journal最新文献

Hypofractionated Particle Therapy: A Review of Clinical Data and Implications. 低分割粒子治疗：临床资料回顾及意义。

IF 2.2 4区医学

Cancer journal Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI: 10.1097/PPO.0000000000000819

Forrest Kwong, Comron Hassanzadeh

引用次数: 0

Radiobiology of Particle Therapy: Revisiting the Preclinical Knowledge Base on Helium Ion Therapy. 粒子治疗的放射生物学：重访氦离子治疗的临床前知识库。

IF 2.2 4区医学

Cancer journal Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI: 10.1097/PPO.0000000000000820

Li Wang, Aron Popovtzer, Albert C Koong, David Grosshans, Michael T Spiotto, Ryan Park, Gabriel O Sawakuchi, Emil Schüler, Radhe Mohan, Steven J Frank

{"title":"Radiobiology of Particle Therapy: Revisiting the Preclinical Knowledge Base on Helium Ion Therapy.","authors":"Li Wang, Aron Popovtzer, Albert C Koong, David Grosshans, Michael T Spiotto, Ryan Park, Gabriel O Sawakuchi, Emil Schüler, Radhe Mohan, Steven J Frank","doi":"10.1097/PPO.0000000000000820","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000820","url":null,"abstract":"Modern photon-based, intensity-modulated radiation therapy (IMRT) kills tumors but may also excessively damage normal tissues; the resultant morbidity can prompt treatment interruptions, worsen tumor control, and degrade quality of life. Charged particles (eg, protons, carbon ions) may be less toxic and more effective than IMRT because particles irradiate less surrounding normal tissues and are more biologically effective than IMRT. However, protons/carbon ions have physical drawbacks that can affect dose precision. Helium ions are being explored as an alternative type of charged-particle therapy because their biophysical characteristics are intermediate between those of protons and carbon ions, potentially improving treatment precision. However, systematic studies of helium ion radiotherapy (HeRT) are scarce. We review current knowledge of the biophysical effects of HeRT: its relative biological effectiveness (RBE) versus photons; its effects on gene mutation, DNA damage and repair, cell cycling, cell death, and radiosensitization; and early explorations of ultra-high dose rate HeRT.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence in Proton Therapy: What Works, What Does Not, and What Is Next. 质子治疗中的人工智能：什么有效，什么无效，下一步是什么。

IF 2.2 4区医学

Cancer journal Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI: 10.1097/PPO.0000000000000821

Heng Li, Ming Yang, Doris Keziah Ndassi, Sizhuo Meng, Xun Jia

{"title":"Artificial Intelligence in Proton Therapy: What Works, What Does Not, and What Is Next.","authors":"Heng Li, Ming Yang, Doris Keziah Ndassi, Sizhuo Meng, Xun Jia","doi":"10.1097/PPO.0000000000000821","DOIUrl":"10.1097/PPO.0000000000000821","url":null,"abstract":"Artificial intelligence is increasingly shaping the evolution of proton therapy, with applications spanning imaging, treatment planning, quality assurance, adaptive workflows, and outcome modeling. Unlike conventional task-specific algorithms, modern AI methods, including machine learning and deep learning, enable integration of heterogeneous data and capture complex relationships across the clinical workflow. These capabilities are particularly relevant in proton therapy, where sensitivity to range uncertainty, anatomic variation, and biological heterogeneity presents persistent clinical and operational challenges. This review summarizes current and emerging AI applications in proton therapy, including image reconstruction and synthesis, segmentation, dose prediction, robustness and uncertainty management, biological optimization, and adaptive treatment strategies. We also discuss the expanding role of AI in quality assurance and workflow coordination, emphasizing the distinction between task-level automation and workflow-level intelligence. Finally, we address broader considerations related to clinical validation, safety, interpretability, economic value, and access, which will be critical for translating AI-enabled proton therapy into routine clinical practice.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13020641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Normal Tissue Complication Probability Modeling for Proton Therapy. 质子治疗的正常组织并发症概率模型。

IF 2.2 4区医学

Cancer journal Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI: 10.1097/PPO.0000000000000814

Mei Chen, Zhongxing Liao, Steven J Frank, Narayan Sahoo, Xiaorong R Zhu, Xiaodong Zhang

{"title":"Normal Tissue Complication Probability Modeling for Proton Therapy.","authors":"Mei Chen, Zhongxing Liao, Steven J Frank, Narayan Sahoo, Xiaorong R Zhu, Xiaodong Zhang","doi":"10.1097/PPO.0000000000000814","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000814","url":null,"abstract":"Proton therapy requires accurate, reliable normal tissue complication probability (NTCP) models for treatment planning and evidence-based patient selection. This review examines 2 challenges in proton therapy: developing NTCP models that accurately reflect proton-specific toxicity and managing NTCP prediction uncertainty to ensure reliable clinical decision-making. Regarding model accuracy, photon-derived NTCP models work for some endpoints but fail for others when proton therapy exhibits distinct dose-response characteristics, indicating that the need for proton-specific models is endpoint-dependent. Clinical evidence that supports updating NTCP models by incorporating variable relative biological effectiveness is statistically weak due to interpatient heterogeneity and inconsistent findings. Despite ongoing efforts in improving NTCP prediction accuracy, the impact of prediction uncertainty on patient selection decisions has received limited attention. Further study is required to establish a robust, model-uncertainty-aware NTCP-guided patient selection framework for proton therapy that addresses both model accuracy and prediction confidence.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introduction from the Guest Editors. 客座编辑的介绍。

IF 2.2 4区医学

Cancer journal Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI: 10.1097/PPO.0000000000000823

Steven J Frank, Li Wang, Xiaorong Ronald Zhu

引用次数: 0

Advancements in Accelerator and Beam Delivery Technology. 加速器和光束传输技术的进展。

IF 2.2 4区医学

Cancer journal Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI: 10.1097/PPO.0000000000000817

Xiaorong R Zhu, Yoshifumi Hojo, Mei Chen, Fahed Alsanea, Falk Poenisch, Yuting Li, Ming Yang, Xiaodong Zhang, Thomas J Whitaker, Narayan Sahoo

引用次数: 0

The Clinical Evidence and Applications of Particle Therapy. 粒子治疗的临床证据及应用。

IF 2.2 4区医学

Cancer journal Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI: 10.1097/PPO.0000000000000822

Anika Patel, Kayeong Shin, Anna Lee

引用次数: 0

Clinical Applications of Particle Therapy in Pediatric Malignancies. 粒子治疗在小儿恶性肿瘤中的临床应用。

IF 2.2 4区医学

Cancer journal Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI: 10.1097/PPO.0000000000000818

Madeline M Flanagan, Ory Haisraely, Arnold C Paulino, Susan L McGovern

引用次数: 0

FLASH Particle Radiotherapy. 闪光粒子放射治疗。

IF 2.2 4区医学

Cancer journal Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI: 10.1097/PPO.0000000000000816

Jufri Setianegara, Ioannis I Verginadis, Constantinos Koumenis, Boon-Keng Kevin Teo, Alexander Lin

{"title":"FLASH Particle Radiotherapy.","authors":"Jufri Setianegara, Ioannis I Verginadis, Constantinos Koumenis, Boon-Keng Kevin Teo, Alexander Lin","doi":"10.1097/PPO.0000000000000816","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000816","url":null,"abstract":"FLASH radiotherapy is an emerging treatment modality characterized by the ultrahigh dose rate delivery of radiation, which has demonstrated the potential to significantly reduce normal tissue toxicity while maintaining tumor control. In cancers traditionally managed with radiotherapy, this approach could improve the therapeutic ratio by mitigating severe side effects associated with current techniques. The integration of particle therapy-such as protons or heavier ions-with FLASH dose rates offers unique physical and biological advantages, including enhanced normal tissue sparing and the possibility of safe dose escalation. Clinical implementation will require a deeper understanding of the mechanistic biological underpinnings of the FLASH effect, alongside advancements in beam delivery systems capable of achieving FLASH dose rates, rigorous quality assurance protocols, and adaptive strategies to accommodate anatomic changes during treatment. Ultimately, widespread clinical adoption will depend on prospective trials comparing FLASH particle therapy with established modalities, with endpoints focused on toxicity, disease control, and patient-reported quality of life.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and Errors in Genetic Testing: The Sixth Case Series. 基因检测的挑战与错误：第六个案例系列。

IF 2.2 4区医学

Cancer journal Pub Date : 2026-03-01 Epub Date: 2026-03-27 DOI: 10.1097/PPO.0000000000000813

Meagan Farmer, Claire McDonald, Darcy K Berry, Danielle Carr, Tanner F Coleman, Matthew J Goldstein, Rebecca Haskins, Jessica Kenney, Kerri Murphy, Rebecca Waggoner, Leah Zaretsky, Danielle Bonadies, Ellen Matloff

{"title":"Challenges and Errors in Genetic Testing: The Sixth Case Series.","authors":"Meagan Farmer, Claire McDonald, Darcy K Berry, Danielle Carr, Tanner F Coleman, Matthew J Goldstein, Rebecca Haskins, Jessica Kenney, Kerri Murphy, Rebecca Waggoner, Leah Zaretsky, Danielle Bonadies, Ellen Matloff","doi":"10.1097/PPO.0000000000000813","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000813","url":null,"abstract":"Purpose: This case series explores ongoing and emerging challenges in genetic testing, focusing on errors and complexities encountered as testing becomes routine across diverse clinical settings.Methods: Cases were solicited from clinicians in multiple specialties via professional networks and social media between 2021 and 2025. Deidentified documentation was reviewed when available, and 15 cases were selected for thematic analysis. Contributors reviewed and approved the representation of their cases.Results: Analysis revealed persistent gaps in communication, coordination, and interpretation of genetic test results. Themes included proactive intervention by genetics professionals, missed opportunities for counseling, evolving complexities in variant interpretation, system failures, delayed diagnoses, and risks of testing without a clear clinical indication. Cases reflected the expanding reach of genetic testing into oncology, primary care, and obstetrics and gynecology, as well as nononcologic contexts.Discussion: The cases highlight the importance of responsible integration of genetic testing into mainstream medical practice. Effective use of digital tools, structured workflows, and interprofessional collaboration is essential to support quality and efficiency. Shared responsibility among providers, laboratories, and technology partners is needed to ensure accurate interpretation and management. Genetic counselors play a central role in designing scalable, high-integrity systems and guiding teams through the complexities of genomic medicine.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0